Crossmark

Low-dose post-transplant cyclophosphamide in combination with low-dose alemtuzumab for graft-versus-host-disease prevention in mismatched unrelated allogeneic stem cell transplantation is associated with improved outcomes and reduced toxicity

Crossref DOI link: https://doi.org/10.1038/s41409-025-02736-6

Published Online: 2025-10-23

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Lazana, Ioanna https://orcid.org/0000-0002-5162-1304
Gkirkas, Konstantinos

Konstantellos, Ioannis

Chatzidimitriou, Chrisovalanto

Karagiannidou, Aggeliki

Gkolfinopoulou, Georgia

Stamouli, Maria

Chondropoulos, Spiros

Tsirigotis, Panagiotis https://orcid.org/0000-0002-3522-3680
License Information

Text and Data Mining valid from 2025-10-23

Version of Record valid from 2025-10-23
More Information

Article History

Received: 16 August 2025

Revised: 4 September 2025

Accepted: 7 October 2025

First Online: 23 October 2025

Competing interests

: The authors declare no competing interests.

: The study was approved by the Institutional Review Board of General University Hospital “Attikon,” Athens, Greece, and was conducted in accordance with the principles of the Declaration of Helsinki (IRB-250730520). Informed consent was obtained from all participants.

Document is current

Any future updates will be listed below